Previous 10 | Next 10 |
SOUTH PLAINFIELD, N.J. , Aug. 7, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the U.S. Food and Drug Administration (FDA) has approved Evrysdi™ (risdiplam), the first at-home, orally administered treatment for spinal muscular atrophy (SMA) in adul...
SOUTH PLAINFIELD, N.J. , Aug. 6, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its Senior Vice President of Corporate and Patient Relations, Mary Frances Harmon , has been named to PharmaVOICE magazine's annual list of the most inspiring people...
PTC Therapeutics, Inc. (PTCT) Q2 2020 Earnings Conference Call August 5, 2020 16:30 ET Company Participants Alex Kane - Head, Investor Relations Stuart Peltz - Chief Executive Officer Emily Hill - Chief Financial Officer Matt Klein - Chief Development Officer Eric Pauwels - C...
PTC Therapeutics (NASDAQ: PTCT ) : Q2 GAAP EPS of -$2.78 misses by $1.48 . More news on: PTC Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH PLAINFIELD, N.J. , Aug. 5, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced a corporate update and reported financial results for the second quarter ending June 30, 2020 . "We are pleased with the progress in our pipeline and the strong commercial ...
SOUTH PLAINFIELD, N.J. , July 22, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter 2020 financial results and provide an update on the company's business and outlook on Wednesday, ...
SOUTH PLAINFIELD, N.J. , July 21, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it will host the second webinar in its deep dive series discussing its therapeutic platforms and programs on Friday, July 24 at 10:00 am ET . The splicin...
Royalty Pharma (NASDAQ: RPRX ) is purchasing ~43% of the royalty up to a specified amount. More news on: Royalty Pharma plc, PTC Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
NEW YORK, July 20, 2020 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today an agreement with PTC Therapeutics, Inc. (Nasdaq: PTCT) to acquire a portion of PTC’s royalty interest in risdiplam for a one-time payment of $650 million. Risdiplam, to be marketed by Ro...
SOUTH PLAINFIELD, N.J. , July 20, 2020 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced an agreement to monetize a portion of the risdiplam royalty stream for $650 million from Royalty Pharma plc. The capital from the collaboration will enable PTC to further de...
News, Short Squeeze, Breakout and More Instantly...
PTC Therapeutics Inc. Company Name:
PTCT Stock Symbol:
NASDAQ Market:
PTC Therapeutics Inc. Website:
PTC Therapeutics Announces Sepiapterin NDA Submission to FDA PR Newswire WARREN, N.J. , July 30, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the submission of the sepiapterin NDA to the U.S. FDA. The NDA submission is for the t...
PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results PR Newswire WARREN, N.J. , July 25, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to r...
2024-07-12 10:00:03 ET Jeffrey Hung from Morgan Stanley issued a price target of $32.00 for PTCT on 2024-07-12 08:15:00. The adjusted price target was set to $32.00. At the time of the announcement, PTCT was trading at $33.2. The overall price target consensus is at $43....